Inhibition of interleukin‐1 with rilonacept is not effective in cold urticaria—Results of a randomized, placebo‐controlled study
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and Translational Allergy"
DOI: 10.1002/clt2.12226
Abstract: Abstract Background Cold urticaria (ColdU) is characterized by pruritic wheals following exposure of the skin to cold. Many patients show insufficient response to antihistamines, the first line treatment. Based on the high efficacy of interleukin‐1(IL‐1)‐inhibition… read more here.
Keywords: inhibition; placebo; rilonacept; cold urticaria ... See more keywords
Comprehensive Clinical Analysis of Rilonacept in the Treatment of Cryopyrin-Associated Periodic Syndromes: A Systematic Review
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Multidisciplinary Healthcare"
DOI: 10.2147/jmdh.s500838
Abstract: Objective Cryopyrin-associated periodic syndromes (CAPS), a group of interleukin-1 (IL-1) mediated autoinflammatory disorders, were incorporated into China’s “Second List of Rare Diseases” in 2023. Notably, rilonacept, an IL-1 inhibitor approved in the United States since… read more here.
Keywords: treatment; cryopyrin associated; systematic review; rilonacept ... See more keywords